Search

everythinglearnresearchcommunity

for

Search:↓

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Early balding at 40 increases prostate cancer risk.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.

Finasteride treats hair loss but may affect prostate cancer detection.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

PSA might help diagnose PCOS and related skin issues, but more research is needed.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.

Smaller finasteride particles increase effectiveness in treating hair loss.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Topical finasteride and flutamide reduce gland size and enzyme activity, with flutamide being more potent, potentially treating acne, seborrhea, hirsutism, and androgenic alopecia.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Saw palmetto supplements may reduce prostate cancer cell growth without being toxic.

A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

KGF and its receptor are found in enlarged prostate tissue and KGF strongly increases cell growth.